Entegris Inc. Executive Chair Retires; New Board Chair and Director Named

What Happened

• Entegris, Inc. announced that Bertrand Loy, Executive Chair of the Board, will retire from his executive role and resign from the Board effective July 31, 2026, upon expiration of his Executive Chair Agreement (dated July 30, 2025). The company said his decision is not due to any disagreement with the company. James F. Gentilcore, the current Lead Independent Director, will become Chair of the Board effective July 31, 2026.
• The Board also appointed Robert A. Bruggeworth (President & CEO of Qorvo, Inc.) as a director effective August 3, 2026 to fill Loy’s vacancy and to serve until the 2027 annual meeting; he will join the Management Development and Compensation Committee.

Key Details

• Retirement/resignation effective: July 31, 2026.
• New director appointment effective: August 3, 2026; term runs until the 2027 annual meeting.
• New director compensation: a prorated equity award with a $220,000 grant-date value in restricted stock units (restrictions lapse on the earlier of the 2027 Annual Meeting or one year after grant) plus a prorated portion of the $110,000 annual non-employee director retainer, paid quarterly, and any committee/chair fees.
• Governance notes: Board determined Bruggeworth is independent under Nasdaq Rule 5605(a)(2). The company will enter into its standard director indemnity agreement with him. The company reported no new compensatory arrangement with Loy in connection with his retirement; his outstanding awards and 2026 incentive will be handled per the Executive Chair Agreement.

Why It Matters

• Leadership and board composition changes can affect investor perception of corporate governance and continuity. The appointment of the existing Lead Independent Director, James Gentilcore, as Chair indicates an internal continuity approach. The addition of an experienced semiconductor industry executive (Robert Bruggeworth) adds outside expertise to the board and to the compensation committee. Compensation and equity grants for the new director are disclosed and prorated, which may have modest near-term equity accounting and governance implications but are routine for non-employee directors.